CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Research suggests this combination reduces side effects and vastly improves outcomes, including weight loss, compared to GLP-1 alone ... gradually decrease the dosage until the medication ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...